What Artis BioSolutions does

Artis BioSolutions is a privately held contract development and manufacturing organization (CDMO) focused on advancing genetic medicines and biologics from early development through commercial readiness. The company serves advanced therapy medicinal product (ATMP) developers—specifically those working in cell and gene therapy, mRNA therapeutics, peptide therapies, and oligonucleotide therapies—through an integrated platform spanning nucleic acid manufacturing, lipid nanoparticle (LNP) formulation, peptide manufacturing, and analytical development services. Artis positions itself as a "growth equity accelerator" rather than a pure transactional CDMO, offering capital support, technical expertise, and a partner network to small and mid-size founder-led companies in North America and Europe.

The company's technical foundation combines organic build-out with targeted acquisitions. In April 2025, Artis emerged from stealth and acquired Landmark Bio, a cell and gene therapy CDMO with GMP manufacturing operations in Watertown, Massachusetts. In January 2026, it acquired Syngoi Technologies—a Spanish biotechnology company founded in 2021 in the Basque Country—from Buenavista Equity Partners and Columbus Venture Partners, gaining a proprietary enzymatic synthetic DNA platform and GMP-ready facilities in Bilbao. These assets are being integrated into a transatlantic manufacturing footprint of seven clinical-to-commercial GMP facilities representing over $250M of deployed capital, anchored by a new synthetic DNA manufacturing hub in Boston launched in March 2026. Leadership comprises founder-CEO Brian Neel (25 years in life sciences/diagnostics), founder-CSO Mike Houston, Ph.D. (oligonucleotide, LNP, and analytical development expertise), CSIO Dr. Kate Broderick, Ph.D. (appointed February 2026 from Maravai LifeSciences and Inovio Pharmaceuticals), CBO Peter Stolba, and SVP of People Leeza Frantz.

Artis generates revenue through professional-services contract manufacturing and development engagements with ATMP sponsors, priced via bespoke quotes rather than public rate cards, and engaged through direct enterprise sales. Its GTM targets founder-led small-to-mid-size therapy developers and corporate partners seeking to scale or commercialize novel products. The company's stated competitive advantages are capital intensity (the seven-facility footprint), proprietary enzymatic DNA synthesis technology from Syngoi, deep talent across multiple modalities (50+ APIs/CRMs developed by leadership), and a dual-region U.S./Europe manufacturing strategy that reduces supply-chain risk for clients.

Name

Artis BioSolutions

Legal name

Artis BioSolutions

Website

https://artisbiosolutions.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

51–100 employees

Short description

Artis BioSolutions is a private CDMO providing GMP manufacturing and development services for advanced therapy developers across cell & gene, mRNA, peptide, and oligonucleotide modalities, operating seven facilities in the U.S. and Europe.

Ownership category

akta.pro rank

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Infrastructure, Personnel, Operations, Technology or R&D, Supply Chain

Revenue model

1. Contract Manufacturing Services (CDMO): Artis BioSolutions generates revenue through contract development and manufacturing services for advanced therapy developers. The company provides GMP manufacturing capabilities across multiple therapeutic modalities including cell & gene therapy, mRNA, peptides, and oligonucleotide therapies, supporting clients from Phase 1 through commercial production.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Artis BioSolutions is a contract development and manufacturing organization (CDMO) that provides GMP manufacturing services for advanced therapy medicinal products (ATMPs) including nucleic acids (synthetic DNA, mRNA, oligonucleotides), lipid nanoparticles (LNPs), peptides, enzymes, and reagents. The company supports drug development from Phase 1 trials through commercial readiness across cell & gene, mRNA, peptide, and oligonucleotide therapy modalities. Services are delivered through seven clinical-to-commercial GMP facilities in the U.S. and Europe via its Landmark Bio (Watertown, MA) and Syngoi Technologies (Bilbao, Spain) entities.

Product overview

Artis BioSolutions is an advanced-therapies development and manufacturing company offering a comprehensive platform for genetic medicines and biologics. The portfolio includes nucleic acid manufacturing services (synthetic DNA, mRNA, oligonucleotides), lipid nanoparticle (LNP) formulation services, peptide manufacturing, and analytical development services. The company operates through two key acquired entities: Landmark Bio (GMP manufacturing facilities in Watertown, MA) and Syngoi Technologies (enzymatic synthetic DNA platform with GMP-ready facilities in Bilbao, Spain). Services support drug development from Phase 1 trials through commercial readiness across diverse modalities including cell & gene therapy, mRNA, peptides, and oligonucleotides. The company has deployed over $250M of capital across seven state-of-the-art clinical to commercial GMP facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Nucleic Acid Manufacturing Services

Quantifiable outcome

• Reduced lead times, logistics costs, and geopolitical/operational risks through dual-region sourcing

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Landmark BiocoreStrategic or Co-development Partner · 1 April 2025Artis BioSolutions acquired Landmark Bio, a cell and gene therapy manufacturer, as part of its emergence from stealth. Landmark Bio operates as a wholly-owned entity of Artis BioSolutions, expanding the company's manufacturing and commercialization capabilities for advanced therapies.
• Syngoi TechnologiescoreStrategic or Co-development PartnerArtis BioSolutions acquired Syngoi Technologies, a Spanish biotechnology company pioneering enzymatic approaches for synthetic DNA manufacturing. Syngoi operates GMP-ready facilities in Bilbao, Spain. The acquisition expands Artis' synthetic DNA capabilities and is part of a dual-sourcing strategy across U.S. and Europe.
• Advanced Therapy Medicinal Product DeveloperscoreOthersArtis BioSolutions partners with and provides services to advanced therapy developers. The company is actively seeking partners with innovative platforms or capabilities that will catalyze success for ATMP developers, with a focus on founder-led companies in North America or Europe.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Resilience: Technology-enabled CDMO focused on advanced therapy manufacturing, including cell, gene and nucleic acid modalities—an emerging challenger with comparable modality breadth and a similar growth-equity profile.

Direct peers

• GenScript ProBio: CDMO division of GenScript offering plasmid DNA, viral vector, mRNA and cell therapy manufacturing—directly comparable to Artis' nucleic acid and cell therapy capabilities.
• Aldevron (Danaher): Leading plasmid DNA, mRNA and protein CDMO serving gene and cell therapy developers—directly comparable to Artis' synthetic DNA and nucleic acid manufacturing offering.
• Lonza: Global CDMO with one of the largest cell, gene and mRNA therapy manufacturing footprints, including mammalian biologics and LNP formulation—Artis' most direct full-service competitor across nucleic acids and advanced therapies.
• Catalent (Novo Holdings): Large diversified CDMO with deep cell and gene therapy capabilities, including viral vector and nucleic acid manufacturing—directly comparable to Artis in advanced therapy modalities.
• TriLink BioTechnologies (Maravai LifeSciences): Specialized nucleic acid CDMO (mRNA, oligonucleotides, plasmid DNA) with GMP-grade synthetic capabilities—Artis' closest direct competitor in the nucleic acid manufacturing niche.
• WuXi Advanced Therapies (WuXi AppTec): Cell and gene therapy CDMO offering viral vector and nucleic acid manufacturing for global ATMP developers—historically the largest competitor to emerging CDMOs, though currently facing US geopolitical headwinds.
• AGC Biologics: Global CDMO offering mammalian biologics and cell/gene therapy manufacturing, including recently expanded viral vector and nucleic acid capacity—a comparable mid-to-large advanced therapy CDMO.

Broad incumbents

• Charles River Laboratories: Established CDMO with a dedicated cell and gene therapy manufacturing business and integrated discovery-to-development services, overlapping Artis' modalities and end customers.
• Samsung Biologics: Large-scale biologics CDMO with growing cell and gene therapy services, providing a broad manufacturing platform that overlaps with Artis' clinical-to-commercial offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/artis-biosolution

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artis BioSolutions